Mesenchymal stem cell therapy for neurological disorders (Medipost)

N/A

Report date: 2023/01/12 15:47:52

Base Information

Drug NameMesenchymal stem cell therapy for neurological disorders (Medipost)
Drug Alias NameNeurostem
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedipost Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMedipost Co Ltd
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A